Jaguar Health announced that patient enrollment has reached approximately 75% in the Company’s pivotal Phase 3 OnTarget clinical trial of crofelemer for prophylaxis of diarrhea in adult cancer patients receiving targeted therapy, with or without chemotherapy. Target trial enrollment of 256 patients is expected to complete in the second quarter of 2023.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on JAGX:
- Jaguar Health announces initial close in private placement financing
- Jaguar Health regains compliance with Nasdaq minimum bid price rule
- Jaguar Health, SynWorld mutually agree to terminate license agreement
- Jaguar Health engages ShareIntel to monitor trading activity
- Jaguar Health enters consulting agreement with Andrew Mulberg
